Research Analysts Set Expectations for Avantor, Inc.’s Q1 2025 Earnings (NYSE:AVTR)

Avantor, Inc. (NYSE:AVTR) – Research analysts at Zacks Research upped their Q1 2025 EPS estimates for shares of Avantor in a report issued on Tuesday, June 25th. Zacks Research analyst D. Dey now forecasts that the company will post earnings of $0.28 per share for the quarter, up from their previous estimate of $0.27. The consensus estimate for Avantor’s current full-year earnings is $1.01 per share. Zacks Research also issued estimates for Avantor’s Q2 2025 earnings at $0.26 EPS and Q1 2026 earnings at $0.32 EPS.

Avantor (NYSE:AVTR) last announced its earnings results on Friday, April 26th. The company reported $0.22 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.20 by $0.02. Avantor had a net margin of 3.79% and a return on equity of 13.01%. The business had revenue of $1.68 billion for the quarter, compared to analyst estimates of $1.68 billion. During the same quarter last year, the business earned $0.29 earnings per share. The company’s revenue for the quarter was down 5.6% compared to the same quarter last year.

Several other equities analysts also recently weighed in on AVTR. Robert W. Baird decreased their target price on Avantor from $27.00 to $26.00 and set an “outperform” rating on the stock in a research report on Monday, April 29th. Barclays decreased their price objective on Avantor from $28.00 to $25.00 and set an “overweight” rating on the stock in a report on Friday. Evercore ISI upped their target price on shares of Avantor from $26.00 to $28.00 and gave the stock an “outperform” rating in a report on Thursday, April 4th. Finally, Deutsche Bank Aktiengesellschaft raised their price target on shares of Avantor from $23.00 to $25.00 and gave the stock a “hold” rating in a research note on Thursday, April 18th. Four research analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Avantor presently has an average rating of “Moderate Buy” and an average target price of $26.36.

Avantor Trading Down 1.1 %

AVTR stock opened at $21.20 on Thursday. Avantor has a 12-month low of $16.63 and a 12-month high of $26.16. The business’s 50-day moving average is $23.73 and its 200 day moving average is $23.79. The company has a current ratio of 1.61, a quick ratio of 1.05 and a debt-to-equity ratio of 0.94. The stock has a market cap of $14.40 billion, a price-to-earnings ratio of 54.35, a PEG ratio of 2.23 and a beta of 1.35.

Institutional Trading of Avantor

Institutional investors have recently made changes to their positions in the company. American Trust grew its position in Avantor by 45.1% in the first quarter. American Trust now owns 13,261 shares of the company’s stock worth $339,000 after acquiring an additional 4,121 shares during the period. Westwood Holdings Group Inc. grew its holdings in shares of Avantor by 10.5% during the 1st quarter. Westwood Holdings Group Inc. now owns 723,084 shares of the company’s stock worth $18,489,000 after purchasing an additional 68,541 shares during the period. DekaBank Deutsche Girozentrale increased its position in shares of Avantor by 146.7% during the 1st quarter. DekaBank Deutsche Girozentrale now owns 400,736 shares of the company’s stock worth $10,205,000 after purchasing an additional 238,285 shares during the last quarter. Boston Partners raised its holdings in Avantor by 2.2% in the 1st quarter. Boston Partners now owns 28,561,802 shares of the company’s stock valued at $729,298,000 after buying an additional 624,369 shares during the period. Finally, Cetera Advisors LLC purchased a new stake in Avantor in the 1st quarter valued at about $249,000. Hedge funds and other institutional investors own 95.08% of the company’s stock.

Avantor Company Profile

Avantor, Inc engages in the provision of mission-critical products and services to customers in the biopharma, healthcare, education and government, advanced technologies, and applied materials industries in the Americas, Europe, Asia, the Middle East, and Africa. The company offers materials and consumables, such as purity chemicals and reagents, lab products and supplies, formulated silicone materials, customized excipients, customized single-use assemblies, process chromatography resins and columns, analytical sample prep kits, education and microbiology products, clinical trial kits, peristaltic pumps, and fluid handling tips.